Defence Therapeutics Stock Performance
| DTCFF Stock | USD 1.00 0.07 7.53% |
Defence Therapeutics holds a performance score of 17 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 2.55, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Defence Therapeutics will likely underperform. Use Defence Therapeutics coefficient of variation, maximum drawdown, skewness, as well as the relationship between the total risk alpha and downside variance , to analyze future returns on Defence Therapeutics.
Risk-Adjusted Performance
Solid
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Defence Therapeutics are ranked lower than 17 (%) of all global equities and portfolios over the last 90 days. Despite nearly weak technical and fundamental indicators, Defence Therapeutics reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 5.5 M |
Defence |
Defence Therapeutics Relative Risk vs. Return Landscape
If you would invest 27.00 in Defence Therapeutics on December 23, 2024 and sell it today you would earn a total of 73.00 from holding Defence Therapeutics or generate 270.37% return on investment over 90 days. Defence Therapeutics is currently producing 2.7143% returns and takes up 12.4948% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than Defence, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Defence Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Defence Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as Defence Therapeutics, and traders can use it to determine the average amount a Defence Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.2172
| Best Portfolio | Best Equity | |||
| Good Returns | DTCFF | |||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 12.49 actual daily | 96 96% of assets are less volatile |
Expected Return
| 2.71 actual daily | 54 54% of assets have lower returns |
Risk-Adjusted Return
| 0.22 actual daily | 17 83% of assets perform better |
Based on monthly moving average Defence Therapeutics is performing at about 17% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Defence Therapeutics by adding it to a well-diversified portfolio.
Defence Therapeutics Fundamentals Growth
Defence OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Defence Therapeutics, and Defence Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Defence OTC Stock performance.
| Return On Equity | -4.15 | |||
| Return On Asset | -1.79 | |||
| Current Valuation | 60.32 M | |||
| Shares Outstanding | 37.85 M | |||
| Price To Book | 36.71 X | |||
| EBITDA | (7.32 M) | |||
| Cash And Equivalents | 506.7 K | |||
| Cash Per Share | 0.01 X | |||
| Book Value Per Share | (0.03) X | |||
| Cash Flow From Operations | (6.04 M) | |||
| Earnings Per Share | (0.15) X | |||
| Total Asset | 719.67 K | |||
About Defence Therapeutics Performance
By analyzing Defence Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Defence Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Defence Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Defence Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Defence Therapeutics Inc., a biotechnology company, engages in the research and development of biologicalbiosimilar therapeutic drugs for cancer and infectious diseases. Defence Therapeutics Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada. Defence Therapeutics is traded on OTC Exchange in the United States.Things to note about Defence Therapeutics performance evaluation
Checking the ongoing alerts about Defence Therapeutics for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Defence Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Defence Therapeutics is way too risky over 90 days horizon | |
| Defence Therapeutics has some characteristics of a very speculative penny stock | |
| Defence Therapeutics appears to be risky and price may revert if volatility continues | |
| Defence Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company has a current ratio of 0.6, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Defence Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Defence Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Defence Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Defence to invest in growth at high rates of return. When we think about Defence Therapeutics' use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (7.34 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Defence Therapeutics has accumulated about 506.7 K in cash with (6.04 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. |
- Analyzing Defence Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Defence Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Defence Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Defence Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Defence Therapeutics' management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of Defence Therapeutics' otc stock. These opinions can provide insight into Defence Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Defence OTC Stock analysis
When running Defence Therapeutics' price analysis, check to measure Defence Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Defence Therapeutics is operating at the current time. Most of Defence Therapeutics' value examination focuses on studying past and present price action to predict the probability of Defence Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Defence Therapeutics' price. Additionally, you may evaluate how the addition of Defence Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |